Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
Author:
Affiliation:
1. Bing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15148
Reference29 articles.
1. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)
2. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database
3. Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
4. Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
5. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Waldenstrom Macroglobulinemia;Reference Module in Biomedical Sciences;2024
2. Advances in Treatment of Waldenström Macroglobulinemia;Current Oncology Reports;2023-10-19
3. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy;Hematology/Oncology Clinics of North America;2023-08
4. Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia;Hematology/Oncology Clinics of North America;2023-08
5. Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia;Frontiers in Immunology;2023-05-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3